New data of the ORION-3 trial demonstrate that twice a year dosing of the siRNA directed at PCSK9 mRNA inclisiran gives sustained and safe lowering of LDL-C by more than 50 percent for up to 3 years, on top of LDL-c lowering therapies.
LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.
A mendelian randomization analysis in population-based cohorts assessed that lowering Lp(a) by 65.7 mg/dL yields a similar CHD event risk reduction as lowering LDL-c by 38.67 mg/dL
In a primary care patient cohort, >50% of patients initiating statin therapy did not show optimal LDL-c lowering, which significantly increased their risk of future CVD events.
In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.
The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use
Mendelian randomization study provides genetic validation for ATP citrate lyase as target (of bempedoic acid) in LDL-c lowering to reduce CV risk, to a similar extent as inhibiting HMGCR with a statin.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.
CME accredited course focussed on PCSK9 inhibitors as novel strategy to reduce LDL-C. Member registration (free) is needed to enroll in this course
A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.